WO2004080396A3 - Liposomal curcumin for treatment of cancer - Google Patents

Liposomal curcumin for treatment of cancer Download PDF

Info

Publication number
WO2004080396A3
WO2004080396A3 PCT/US2004/006832 US2004006832W WO2004080396A3 WO 2004080396 A3 WO2004080396 A3 WO 2004080396A3 US 2004006832 W US2004006832 W US 2004006832W WO 2004080396 A3 WO2004080396 A3 WO 2004080396A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
curcumin
cancer
delivery system
treatment
Prior art date
Application number
PCT/US2004/006832
Other languages
French (fr)
Other versions
WO2004080396A2 (en
Inventor
Razelle Kurzrock
Lan Li
Kapil Mehta
Bharat Bhushan Aggarwai
Original Assignee
Univ Texas Md Anderson Cancer
Razelle Kurzrock
Lan Li
Kapil Mehta
Bharat Bhushan Aggarwai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas Md Anderson Cancer, Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwai filed Critical Univ Texas Md Anderson Cancer
Publication of WO2004080396A2 publication Critical patent/WO2004080396A2/en
Publication of WO2004080396A3 publication Critical patent/WO2004080396A3/en
Priority to US11/221,179 priority Critical patent/US7968115B2/en
Priority to US11/868,251 priority patent/US20080103213A1/en
Priority to US11/949,027 priority patent/US8784881B2/en
Priority to US13/117,807 priority patent/US9283185B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
PCT/US2004/006832 2003-03-07 2004-03-05 Liposomal curcumin for treatment of cancer WO2004080396A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/221,179 US7968115B2 (en) 2004-03-05 2005-09-07 Liposomal curcumin for treatment of cancer
US11/868,251 US20080103213A1 (en) 2004-03-05 2007-10-05 Liposomal curcumin for treatment of neurofibromatosis
US11/949,027 US8784881B2 (en) 2004-03-05 2007-12-01 Liposomal curcumin for treatment of diseases
US13/117,807 US9283185B2 (en) 2003-03-07 2011-05-27 Liposomal curcumin for treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45263003P 2003-03-07 2003-03-07
US60/452,630 2003-03-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11221179 A-371-Of-International 2004-03-05
US13/117,807 Continuation US9283185B2 (en) 2003-03-07 2011-05-27 Liposomal curcumin for treatment of cancer

Publications (2)

Publication Number Publication Date
WO2004080396A2 WO2004080396A2 (en) 2004-09-23
WO2004080396A3 true WO2004080396A3 (en) 2004-12-02

Family

ID=32990665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006832 WO2004080396A2 (en) 2003-03-07 2004-03-05 Liposomal curcumin for treatment of cancer

Country Status (1)

Country Link
WO (1) WO2004080396A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
ES2427216T3 (en) * 2006-03-06 2013-10-29 The Regents Of The University Of California Bioavailable curcuminoid formulations for the treatment of Alzheimer's disease and other age-related disorders
EP2076129B1 (en) 2006-10-12 2016-05-04 Research Foundation Of The City University Of New York Novel curcumin dimer
DK2104659T3 (en) * 2007-01-08 2015-11-02 Allianz Pharmascience Ltd Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
CN101569607B (en) * 2009-06-16 2011-02-16 中国药科大学 Di-demethoxycurcumin precursor liposome and preparation method thereof
WO2011101859A1 (en) * 2010-02-22 2011-08-25 Institute Of Life Sciences A novel water soluble curcumin loaded nanoparticulate system for cancer therapy
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
WO2012024405A2 (en) * 2010-08-17 2012-02-23 The Ohio State University Curcumin compositions and uses thereof
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
WO2012167212A2 (en) 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
CA2882978A1 (en) 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
WO2014192024A1 (en) * 2013-05-20 2014-12-04 Sree Chitra Tirunal Institute For Medical Sciences And Technology Development of soluble albuminated curcumin for application in cancer therapy
JP6895252B2 (en) 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. Liposomal reduction of drug-induced inhibition of myocardial IKR channels
PL3225112T3 (en) 2016-04-01 2022-01-03 Trioptotec Gmbh Photosensitiser dispersion and use of the same
WO2017189424A2 (en) 2016-04-27 2017-11-02 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
KR102127852B1 (en) * 2016-06-13 2020-06-30 차이나 메디컬 유니버시티 New derivatives of curcuminoids and their use as anticancer agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
DE10029770A1 (en) * 2000-06-16 2001-12-20 Transmit Technologietransfer Treatment of solid tumors, especially brain tumors, using curcumin or derivative to inhibit peritumoral edema and tumor growth and kill the tumor cells
WO2002002582A1 (en) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
DE10029770A1 (en) * 2000-06-16 2001-12-20 Transmit Technologietransfer Treatment of solid tumors, especially brain tumors, using curcumin or derivative to inhibit peritumoral edema and tumor growth and kill the tumor cells
WO2002002582A1 (en) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG M.-T. ET AL: "Inhibitory effects of curcumin on tumor initiation by benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene", CARCINOGENESIS, vol. 13, no. 11, 1992, pages 2183 - 2186, XP008044662 *
KUTTAN R. ET AL: "Potential anticancer activity of turmeric (curcuma longa)", CANCER LETTERS, vol. 29, 1985, pages 197 - 202, XP001120343 *
RANADE V.V.: "Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers", J. CLIN. PHARMACOL., vol. 29, 1989, pages 685 - 694, XP002982134 *
SAMABA H.S. ET AL: "Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion", CANCER RESEARCH, vol. 57, April 1997 (1997-04-01), pages 1301 - 1305, XP002982133 *

Also Published As

Publication number Publication date
WO2004080396A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2004080396A3 (en) Liposomal curcumin for treatment of cancer
WO2004089336A3 (en) Drug delivery systems comprising an encapsulated active ingredient
WO2003082247A3 (en) Drug microparticles
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2002070438A3 (en) Compositions for delivering bisphosphonates
EP2322217A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
MY141584A (en) Pharmaceutical uses of bisphosphonates
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
MXPA05007266A (en) Pharmaceutical preparations for treatments of diseases and disorders of the breast.
AU3468900A (en) Cyclodextrin polymers for use as drug carriers
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
WO2003057916A3 (en) Cancer profiles
HUP0203590A2 (en) Remedies for diseases in association with decrease in bone mass
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
DK1392254T3 (en) Micelle drug delivery system for hydrophobic drugs
WO2002089778A3 (en) Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
HK1068606A1 (en) Novel aminobenzoephenones
MXPA04002714A (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug.
TW200509998A (en) Controlled release of highly soluble agents
CA2585754C (en) Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy
WO2005094790A8 (en) Liposomal formulations
WO2005027936A3 (en) Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
WO2003039437A3 (en) Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11221179

Country of ref document: US

122 Ep: pct application non-entry in european phase